Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Abstract

Docetaxel 75 mg/m2 over 1 hour followed by cisplatin 75 mg/m2 over 1 hour is recommended for phase II studies. The responses seen in this phase I study suggest a high degree of activity of this combination in previously untreated advanced NSCLC.